Drug Profile


Alternative Names: PAT-LM1

Latest Information Update: 23 Apr 2014

Price : $50

At a glance

  • Originator Patrys
  • Class Antibodies; Antineoplastics
  • Mechanism of Action NONO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Solid tumours

Most Recent Events

  • 23 Apr 2014 PAT LM1 is available for licensing as of 23 Apr 2014.
  • 24 Mar 2014 Preclinical trials in Haematological malignancies prior to March 2014 in Australia (Parenteral)
  • 24 Mar 2014 Pharmacodynamics data from a preclinical studies in Haematological maligancies released by Patrys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top